Isoxadixyl Microcapsule Suspension and Its Preparation Method
The preparation of biodegradable microcapsule suspensions has solved the problems of stability and release control in isoxaflutole pesticide formulations, achieving high encapsulation efficiency and pesticide loading, reducing environmental risks and application dosage, and making it suitable for green agricultural production.
Patent Information
- Application Number
- CN202611078872.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing isoxaflutole pesticide formulations have problems such as droplet drift, high risk of phytotoxicity, environmental pollution, high risk of storage and transportation safety, and poor stability. Furthermore, the microcapsule preparation process is unstable, resulting in microcapsules agglomerating into clumps, low pesticide loading, and poor sustained-release performance.
The microcapsule suspension is made of isoxaflutole and solvent as the core and biodegradable composite resin as the capsule wall. It is prepared by in-situ polymerization and composite emulsifying agent is added to regulate the release rate and optimize the capsule wall formation and dispersibility.
It improves the encapsulation efficiency and drug loading of microcapsules, has good stability, reduces evaporation drift toxicity, realizes controlled release and environmentally friendly pesticide application, and reduces application dosage and environmental impact.
Smart Images

Figure CN123100607A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pesticide formulation technology, and particularly relates to a biodegradable microcapsule suspension containing isoxaflutole as an active ingredient and its preparation method. Background Technology
[0002] In modern agricultural production, herbicides are essential agricultural inputs for controlling weeds and ensuring crop yields. Low toxicity, slow-release, and environmentally friendly formulations are the main trends in pesticide development. Isoxaflutole (structure shown in attached image) Figure 1 (As shown) is a highly effective, broad-spectrum, and selective herbicide. It is absorbed and translocated through the roots and shoots of weeds, inhibiting the activity of isoprene pyrophosphate isomerase and geraniylgeraniyl pyrophosphate synthase, thus blocking chlorophyll biosynthesis and causing weed leaves to whiten and die. It is suitable for fields of various crops such as soybeans, corn, peanuts, sugarcane, and rapeseed, and has good control effects on both broadleaf and grassy weeds. It features convenient application, long-lasting effect, broad spectrum of weed control, and is not limited by the weed germination stage, making it widely used in agricultural weed control.
[0003] However, conventional formulations of isoxaflutole, such as emulsifiable concentrates and aqueous solutions, have significant shortcomings: After application, the pesticide is prone to droplet and vapor drift, leading to low application efficiency and requiring larger dosages; furthermore, it can cause leaf whitening and phytotoxicity in sensitive crops like cotton, grapes, and watermelons. Additionally, its long residual period in the soil can negatively impact the growth of subsequent crops such as wheat, sugar beets, and potatoes, reducing crop rotation efficiency; frequent application is required, increasing agricultural production costs and environmental burden; and the high content of organic solvents like toluene and xylene in the formulations poses environmental pollution and safety risks during storage, transportation, and use. These issues limit the further application of isoxaflutole in green agricultural production.
[0004] Microencapsulation technology for pesticides effectively addresses the shortcomings of traditional formulations. This technology uses polymer materials to encapsulate the active pesticide ingredient, achieving a slow and controlled release. It offers advantages such as reduced volatility, extended duration of action, reduced phytotoxicity, improved stability, and protection of the active ingredient. Current microencapsulation preparation methods include coagulation, interfacial polymerization, in-situ polymerization, solvent evaporation, and spray drying. These processes typically involve multiple steps and have stringent requirements for reaction conditions such as pH, temperature, stirring speed, and phase ratio, which can easily lead to microencapsulation clumping or excessive free pesticide content, resulting in poor batch-to-batch stability.
[0005] A preliminary search of isoxaflutole microencapsulation formulations revealed several shortcomings in current research. For example, an improper ratio of wall material to core can lead to incomplete encapsulation, microcapsule aggregation, low drug loading, poor sustained-release performance, or incomplete release. Furthermore, urea-formaldehyde resin wall microcapsules are prone to stratification and precipitation, exhibiting rapid sedimentation, uneven surface morphology, and poor stability. Therefore, it is necessary to research and develop isoxaflutole microencapsulation formulations with better process stability, storage stability, and controllable release behavior. Summary of the Invention
[0006] The purpose of this invention is to address the aforementioned technical problems by providing an isoxaflutole microcapsule suspension with high encapsulation efficiency, good process stability, controllable release rate, and biodegradable capsule walls, as well as its preparation method. Through long-term and in-depth research, the researchers of this invention have discovered that the above-mentioned problems can be solved by using certain composite stabilizing agents.
[0007] In view of this, the present invention proposes an isoxaflutole biodegradable microcapsule suspension, comprising biodegradable microcapsules and a composite emulsifying agent; the biodegradable microcapsule comprises a core and a wall, the core being isoxaflutole and a solvent, and the wall being a biodegradable composite resin composed of a resin-based encapsulation material and a bio-based encapsulation material.
[0008] Optionally, the solvent in the capsule core is selected from one or more of soybean oil, peanut oil, olive oil, camellia oil, sunflower seed oil, pine oil, rapeseed oil, cottonseed oil, N-methylpyrrolidone (NMP), N,N-dimethylformamide (DMF), cyclohexanone, ethyl acetate, and n-butanol, and the mass fraction of isoxaflutole in the capsule core is 20-50%.
[0009] Optionally, the mass ratio of the core to the resin-based capsule material is 1:1 to 3.
[0010] Optionally, the mass ratio of the core to the bio-based encapsulation material is 1:0.4~1.
[0011] Further, the resin-based capsule material is melamine resin or urea-formaldehyde resin. When the resin-based capsule material is melamine resin, the mass ratio of melamine resin to bio-based capsule material is 1:0.2-0.5; when the resin-based capsule material is urea-formaldehyde resin, the mass ratio of urea-formaldehyde resin to bio-based capsule material is 1:0.5-1.
[0012] Optionally, the composite emulsifying agent includes an emulsifier and a dispersant. The emulsifier is selected from one or more of corn protein, chickpea protein, pea protein, soy protein, casein, and whey protein. The dispersant is selected from one or more of gelatin, glycerin, and povidone. Preferably, the dispersant is composed of gelatin, glycerin, and povidone in a mass ratio of 3:2:1.
[0013] Furthermore, the components in the composite emulsifying agent can be used as bio-based encapsulation materials to participate in the composite of resin-based encapsulation materials.
[0014] As one of the preferred embodiments of the aforementioned isoxaflutole biodegradable microcapsule suspension, the isoxaflutole biodegradable microcapsule suspension is prepared by in-situ polymerization, and the specific preparation method includes the following steps: (1) Preparation of resin-based capsule material prepolymer; (2) Mix isoxaflutole technical grade drug with solvent thoroughly to obtain core solution; (3) Mix the core solution and resin-based capsule material prepolymer evenly, adjust the pH of the system to 3.8~4.0; add composite emulsifying agent, and polymerize in situ under stirring conditions; (4) Stir and solidify at 60~70℃ and 800~1500rpm for 60~90min; adjust the pH of the system to neutral to obtain the final product.
[0015] The amount of composite emulsifying agent added is 20-70% of the weight of the resin-based capsule material.
[0016] More specifically, when the resin-based encapsulating material is a melamine microencapsulation agent, the preparation method includes the following steps: Preparation of S1 melamine resin prepolymer: The pH of formaldehyde solution was adjusted to 8.0-8.5 using triethanolamine aqueous solution, melamine was added, and the molar ratio of formaldehyde to melamine was controlled at 2.9-3.1:1. The mixture was stirred at 70-80℃ and 800-1300rpm for 30min to obtain a clear and transparent melamine resin prepolymer. S2 Isoxabine solvent preparation: The isoxabine technical material and solvent are thoroughly mixed to obtain the capsule core; S3 Dispersion Modification: The isoxaflutole capsule core and melamine resin prepolymer were mixed evenly according to a core-to-wall mass ratio of 1:1 to 1:3. The pH of the system was adjusted to 3.8-4.0 using an acetic acid aqueous solution, and a composite emulsifying agent was added. The mixture was stirred at 500 rpm for 15-30 min. The amount of composite emulsifying agent added was 20-40% of the mass of the melamine resin prepolymer. S4 microcapsule curing: Curing is carried out by stirring at 60~70℃ and 800~1500rpm for 60~90min; the pH of the system is adjusted to neutral with a weak alkali to obtain the final product.
[0017] More specifically, when the resin-based capsule material is urea-formaldehyde resin, the preparation method includes the following steps: Preparation of S1 urea-formaldehyde resin prepolymer: The pH of formaldehyde solution was adjusted to 8.0-8.5 using triethanolamine aqueous solution, urea was added, and the mixture was stirred at 70-80℃ and 800-1300rpm to obtain urea-formaldehyde resin prepolymer; wherein the molar ratio of urea to formaldehyde was 1.8-2.2:1. S2 Isoxabine solvent preparation: The isoxabine technical material and solvent are thoroughly mixed to obtain the capsule core; S3 Dispersion Modification: The isoxaflutole capsule core and urea-formaldehyde resin prepolymer were mixed evenly according to a mass ratio of capsule core to urea-formaldehyde resin capsule wall of 1:1 to 1:2; the pH of the system was adjusted to 3.8 to 4.0 with dilute hydrochloric acid, and a composite emulsifying agent was added. The mixture was stirred at 40°C and 800 rpm for 15 to 30 minutes; the amount of the composite emulsifying agent added was 60 to 70% of the mass of the urea-formaldehyde resin prepolymer. S4 microcapsule curing: Heat to 60~70℃ and stir for 30 minutes at 800~1500rpm to complete the capsule wall curing. Adjust the pH of the system to neutral with a weak alkali to obtain the product.
[0018] This invention prepares two isoxaflutole microcapsule suspensions with different properties through in-situ polymerization: melamine resin wall material microcapsules have narrow particle size distribution, smooth and flat surface, and thick and dense shell; urea-formaldehyde resin wall material microcapsules have controllable morphology and moderate shell thickness. Both types of microcapsules are fully formed and uniformly dispersed.
[0019] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0020] 1. The present invention uses an in-situ polymerization method to add one or more composite stabilizing agents during the curing and molding process of melamine resin and urea-formaldehyde resin to prepare isoxaflutole biodegradable microcapsule suspension with an encapsulation rate of over 80% and a drug loading of over 20%, and good process stability. This invention solves the problems of incomplete encapsulation, agglomeration and adhesion, and irregular morphology of existing microcapsules.
[0021] 2. By adjusting the dosage and ratio of the composite stabilizing agent, this invention can improve the stability of the suspension and regulate the release rate of the isoxaflutole biodegradable microcapsule suspension.
[0022] 3. The isoxaflutole biodegradable microcapsule suspension of the present invention can reduce the toxicity caused by evaporation drift and be applied to crops more effectively, thereby reducing the dosage.
[0023] 4. The isoxaflutole biological microcapsule suspension of the present invention introduces natural protein-based stabilizing components into the capsule wall, which are biodegradable in the environment, reducing both short-term and long-term environmental impacts. Attached Figure Description
[0024] Figure 1 The chemical structural formula of isoxaflutole is given.
[0025] Figure 2 This is a schematic diagram illustrating the synthesis reaction of melamine resin prepolymer and the principle of microcapsule formation.
[0026] Figure 3The images show the optical microscopic morphology of isoxaflutole melamine microcapsules under different processing conditions; Figures a and b show the core-to-wall mass ratio of 1:1.8, Figure c shows the core-to-wall mass ratio of 1:0.6, and Figure d shows the core-to-wall mass ratio of 1:1.8 without the addition of composite stabilizing agents.
[0027] Figure 4 The core-to-wall mass ratio is 1:1.8 for isoxaflutole biodegradable melamine microcapsule suspension released into the soil.
[0028] Figure 5 The images show a comparison of the morphology of isoxaflutole urea-formaldehyde resin microcapsules; Figure a is an optical microscope image of the hollow urea-formaldehyde resin capsules (400x magnification), Figure b is an optical microscope image of the hollow urea-formaldehyde resin capsules (100x magnification), Figure c is an optical microscope image of the drug-containing urea-formaldehyde resin microcapsules (400x magnification), and Figure d is a transmission electron microscope image of the drug-containing urea-formaldehyde resin microcapsules.
[0029] Figure 6 Soil release of isoxaflutole biodegradable urea-formaldehyde microcapsule suspension with different core-to-wall ratios. Detailed Implementation
[0030] The technical solution and effects of the present invention are further illustrated below through specific embodiments. The experimental reagents and instruments used in the embodiments of the present invention are all commercially available conventional products, and the operating methods not specifically described are all conventional techniques in the art.
[0031] In the description of this application, it should be noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the exemplary embodiments according to this application. Techniques, methods, and devices known to those skilled in the art may not be discussed in detail, but where appropriate, such techniques, methods, and devices should be considered part of the specification. In all examples shown and discussed herein, any specific values should be interpreted as merely exemplary and not as limitations. Therefore, other examples of exemplary embodiments may have different values.
[0032] Experimental reagents: Isoxaflutole technical grade (93% by mass, melting point 25℃); urea (analytical grade); formaldehyde solution (37% by mass, analytical grade); triethanolamine (pharmaceutical excipient); melamine (analytical grade); sodium hydroxide (analytical grade); corn gluten (Sigma, Lot# SLBD5665V); casein (Sigma, Lot# SLBG8143V); povidone (PVP-K15); Tween-80 (pharmaceutical grade); anhydrous ethanol (analytical grade); glycerin (analytical grade); gelatin (CAS 9000-70-8, chemically pure); glacial acetic acid (analytical grade); concentrated hydrochloric acid (analytical grade).
[0033] Experimental instruments: Thermostatic magnetic stirrer; electronic analytical balance (accuracy 0.0001g); pH meter; high performance liquid chromatograph; laser particle size analyzer; optical microscope; transmission electron microscope; centrifuge. Example 1
[0034] 14.6 g of 37% formaldehyde solution and 126 mL of deionized water were added to a three-necked flask. The pH of the system was adjusted to 8.0 with 20% triethanolamine aqueous solution. 7.6 g of melamine was added and stirred until the solid was completely dissolved. The temperature was raised to 80°C and the reaction was carried out at 1300 rpm for 30 min to obtain a clear and transparent melamine resin prepolymer.
[0035] In a separate beaker, add 5g of isoxaflutole technical grade and 5g of soybean oil, heat to 50℃, and stir at 1300rpm for 30min to obtain 10g of homogeneous and stable isoxaflutole immiscible capsule core.
[0036] 10g of the isoxaflutole and water-immiscible capsule core were poured into the melamine resin prepolymer (core-to-wall ratio approximately 1:1.3). After stirring and mixing thoroughly, a 10% (w / w) aqueous acetic acid solution was slowly added dropwise to adjust the pH of the system to 3.8, with the addition process completed within 15 minutes. A composite stabilizing agent was added to the system, resulting in a final system containing 2g corn protein, 1.5g gelatin, 1.0g glycerin, and 0.5g povidone. The mixture was stirred at 500 rpm for 15 minutes. Subsequently, the temperature was raised to 70℃, and the mixture was stirred at 1300 rpm for 90 minutes to cure, yielding a melamine resin wall material isoxaflutole microcapsule suspension. Figure 2 ).
[0037] The microcapsule particle size distribution obtained in this embodiment is 2.40–2.80 μm. Figure 3 (a, 3b) The D50 was 2.60 μm, the particle size distribution spanned 0.150, the surface was smooth and flat, and the shell thickness, as measured by transmission electron microscopy, was 125–135 nm. There was no agglomeration or adhesion, and the dispersibility was good. In three parallel measurements, the average microcapsule encapsulation efficiency was 85.0 ± 5.3%, and the average drug loading was 24.0 ± 2.6% (N=3).
[0038] Simulated field trial: 500 mg of isoxaflutole microcapsule suspension was placed in a filter bag, covered with soil, and samples were taken at 0.5, 1, 2, 3, 5, 7, 15, and 35 days. The isoxaflutole content was determined by HPLC. Chromatographic conditions were: column: Vision HTC18 HL (250 mm * 4.6 mm, 5 µm), flow rate: 1 mL / min, injection volume: 20 µL, column temperature: 30℃, mobile phase: methanol:water = 75:25. The results of the 35-day simulated field trial are as follows: Figure 4 As shown. Example 2
[0039] The preparation steps in this embodiment are basically the same as those in Example 1, except that the mass ratio of the capsule core to the melamine capsule wall in the microcapsule curing step is adjusted to 1:1.8.
[0040] The prepared microcapsules had a particle size distribution of 2.45–2.75 μm, a D50 of 2.60 μm, a particle size distribution range of 0.130, a smooth surface, a shell thickness of 125–135 nm, and good dispersibility. The average encapsulation efficiency was 83.5 ± 4.6%, and the average drug loading was 25.2 ± 3.1% (N=3). Example 3
[0041] The preparation steps in this embodiment are basically the same as those in Example 1, except that the mass ratio of the capsule core to the melamine capsule wall in the microcapsule curing step is adjusted to 1:2.3.
[0042] The prepared microcapsules had a particle size distribution of 2.50–2.80 μm, a smooth and dense surface, a shell thickness of 130–140 nm, and good structural stability. The average encapsulation efficiency was 80.6 ± 4.9%, and the average drug loading was 19.7 ± 3.4% (N=3). Comparative Example 1
[0043] This comparative example is identical to Example 1 in all steps and parameters except that the mass ratio of the capsule core to the melamine capsule wall is adjusted to 1:0.6. Experimental results show that under these conditions, the microcapsule walls do not completely encapsulate the contents. Figure 3 c) The isoxaflutole technical grade drug exhibited redundant adhesion and extremely uneven particle size distribution, failing to form a complete microcapsule structure. The encapsulation efficiency was only 32.0±6.3%, and the average drug loading was 7.8±1.9% (N=3). Comparative Example 2
[0044] This comparative example is identical to Example 1 in all steps and parameters except for the absence of a composite stabilizing agent. The resulting microcapsules exhibited partial aggregation. Figure 3 d) The capsule wall thickness is uneven, the dispersibility is poor, the encapsulation efficiency is only 19.2±3.1%, and the average drug loading is 4.8±0.9% (N=3). Comparative Example 3
[0045] The preparation steps of this comparative example are basically the same as those of Example 1, except that the emulsifier corn protein in the composite stabilizing agent is not added. The final system contains 1.5g of stabilizer gelatin, 1g of glycerin and 0.5g of povidone.
[0046] The prepared microcapsules exhibited partial aggregation, uneven capsule wall size, poor dispersibility, and an encapsulation efficiency of only 35.6%, with an average drug loading of 5.2%. Comparative Example 4
[0047] The difference between this comparative example and Example 1 is that a composite stabilizing agent was added to the system, resulting in a final system containing 2g of corn gluten, 1g of gelatin, 1g of glycerol, and 1g of povidone. The resulting microcapsules had a wide particle size distribution, ranging from 3.10 to 5.00 μm, with a particle size distribution span of 0.412. The average encapsulation efficiency was 65%, and the average drug loading was 13.4%. Example 4
[0048] Add 5g of urea, 13g of 37% formaldehyde solution and 130mL of deionized water to a three-necked flask, adjust the pH of the system to 8.2 with 20% triethanolamine aqueous solution, heat to 70℃, stir at 800rpm for 60min to obtain a clear and transparent urea-formaldehyde resin prepolymer.
[0049] Weigh out 3g of isoxaflutole raw material and prepare 6g of water-immiscible capsule cores with 3g of cyclohexanone.
[0050] Isoxaflutole capsule cores were added dropwise to urea-formaldehyde resin prepolymer (core-to-wall ratio approximately 1:1.6) over a period of 30 minutes. After addition, the mixture was stirred at 1500 rpm for 60 minutes to form a stable O / W emulsion. The pH of the system was adjusted to 4.0 using a 5% hydrochloric acid aqueous solution. A composite stabilizing agent was added to ensure the final system contained 3g casein, 1.5g gelatin, 1.0g glycerol, and 0.5g povidone. The mixture was stirred at 40℃ and 800 rpm for 30–60 minutes. The temperature was then raised to 60℃, and stirring continued for another 30–60 minutes to solidify the capsule walls. Finally, the pH of the system was adjusted to neutral using a 20% sodium hydroxide aqueous solution, yielding the isoxaflutole microcapsule suspension for urea-formaldehyde wall materials.
[0051] The microcapsules prepared in this embodiment have a particle size distribution of 3.0–5.0 μm, a D50 of 4.2 μm, a particle size distribution span of 0.250, and a surface with wrinkles and depressions. Figure 5 The shell thickness, measured by transmission electron microscopy, was 187.8 nm. Figure 5 d) The sedimentation stability was good. In three parallel determinations, the average microcapsule encapsulation efficiency was 82.0 ± 4.6%, and the average drug loading was 23.1 ± 2.5%. The release rate of the active ingredient reached 96.2% within 30 days. Figure 6 ). Example 5
[0052] The preparation steps in this embodiment are basically the same as in Example 4, except that the mass ratio of the capsule core to the urea-formaldehyde capsule wall in the mixing and emulsification step is adjusted to 1:0.4. The resulting microcapsule walls are relatively thin, the particle size distribution is uneven, and the sustained-release rate is too fast, with the effective ingredient release rate reaching 92.0% within 15 days. Figure 6The average encapsulation efficiency was 57.5 ± 3.2%, and the average drug loading was 12.7 ± 2.1%. Example 6
[0053] The preparation steps in this embodiment are basically the same as in Example 4, except that the mass ratio of the capsule core to the urea-formaldehyde capsule wall in the mixing and emulsification step is adjusted to 1:3. The resulting microcapsule walls are too thick, the overall particle size is too large, and the isoxaflutole release rate is too slow, with the effective ingredient release rate only reaching 45% within 30 days. Figure 6 The average encapsulation efficiency was 84.2 ± 3.6%, and the average drug loading was 21.3 ± 1.8%. Example 7
[0054] To determine the appropriate emulsification system for the microcapsule preparation of this invention, a control experiment was conducted using emulsifiers. The dispersibility, agglomeration degree, and encapsulation rate of urea-formaldehyde resin microcapsules were used as evaluation indicators. The results showed that: when using a protein-based emulsifier alone, the microcapsules exhibited slight agglomeration, with moderate dispersibility and an encapsulation rate of 72%. The sedimentation rate of the prepared microcapsules was significantly accelerated, reaching a sedimentation volume ratio of 15% after 30 days of standing, and stratification was easily observed, indicating poor stability. When using povidone alone as an emulsifier, the emulsification effect was poor, the capsule core could not be uniformly dispersed, and the encapsulation rate was only 51%. When using gelatin alone as an emulsifier, the microcapsule particle size was uneven, and sedimentation was very easy, with an encapsulation rate of 65%. When using glycerol alone, there was no significant emulsification effect, and a complete microcapsule structure could not be formed. Therefore, it is evident that a single emulsifier cannot meet the preparation requirements of the isoxaflutole microcapsules of this invention, and a compound system of emulsifiers and specific dispersants is needed to improve the emulsification and dispersion effect.
[0055] Based on the above screening results for single emulsifiers, with the total amount of emulsifier remaining constant, the mass ratio of povidone to protein emulsifier was adjusted. Comparative experiments were conducted using microcapsule dispersibility, agglomeration degree, and particle size uniformity as evaluation indicators. The results are as follows: When the mass ratio was 1:3, slight agglomeration of microcapsules still occurred, with an encapsulation rate of 78%; when the mass ratio was 1:2, no agglomeration occurred, and the microcapsules were uniformly dispersed, with an encapsulation rate reaching 89%; when the mass ratio was 1:1, no agglomeration occurred, and the microcapsules were uniformly dispersed, with the highest encapsulation rate reaching 90%; when the mass ratio was 2:1, the dispersibility of microcapsules decreased, a small amount of agglomeration occurred, and the encapsulation rate dropped to 82%. The experimental results indicate that when povidone and emulsifier are combined in a mass ratio of 1:1 to 1:2, they can exert a synergistic effect, significantly improving the emulsification and dispersion effect and effectively solving the microcapsule agglomeration problem. Example 8
[0056] Except for the absence of protein emulsifier in the mixing and emulsification step, all other steps and parameters in this embodiment are the same as in Example 4. Experimental results show that under these conditions, the microcapsule emulsification effect is uneven, the morphology is irregular, the core encapsulation rate is low, and the encapsulation efficiency is only 58.0±15.4%. Example 9
[0057] Under sealed conditions at room temperature, urea-formaldehyde microcapsules remained clear and transparent for 6 months without stratification or sedimentation; melamine microcapsules showed slight turbidity after 7 days, and it is recommended to prepare and use them immediately. Both types of microcapsules showed some degree of sedimentation during storage, with urea-formaldehyde microcapsules settling slightly faster than melamine microcapsules. Adding compound adjuvants effectively delayed microcapsule sedimentation. After 30 days of standing, the sedimentation volume ratio of melamine microcapsules was 3%, and that of urea-formaldehyde microcapsules was 5%, both meeting the storage requirements for pesticide formulations.
[0058] The embodiments of this application have been described above with reference to the accompanying drawings. Unless otherwise specified, the embodiments and features in the embodiments of this application can be combined with each other. This application is not limited to the specific embodiments described above. The specific embodiments described above are merely illustrative and not restrictive. Those skilled in the art can make many other forms under the guidance of this application without departing from the spirit and scope of the claims, and all of these forms are within the protection scope of this application.
Claims
1. A biodegradable microcapsule suspension of isoxaflutole, characterized in that, The invention includes biodegradable microcapsules and a composite emulsifying agent; the biodegradable microcapsules include a core and a wall, the core being isoxaflutole and a solvent, and the wall being a biodegradable composite resin composed of a resin-based encapsulating material and a bio-based encapsulating material; the components of the composite emulsifying agent can be used as a composite of the bio-based encapsulating material and the resin-based encapsulating material.
2. The isoxaflutole biodegradable microcapsule suspension according to claim 1, characterized in that, The resin-based capsule material is melamine resin or urea-formaldehyde resin.
3. The isoxaflutole biodegradable microcapsule suspension according to claim 1, characterized in that, The composite emulsifying agent includes an emulsifier and a dispersant; wherein the emulsifier is selected from one or more of corn protein, chickpea protein, pea protein, soy protein, casein, and whey protein; and the dispersant is selected from one or more of gelatin, glycerin, and povidone.
4. The isoxaflutole biodegradable microcapsule suspension according to claim 3, characterized in that, The dispersant is composed of gelatin, glycerin, and povidone in a mass ratio of 3:2:
1.
5. The isoxaflutole biodegradable microcapsule suspension according to claim 1, characterized in that, The solvent in the capsule core is selected from one or more of soybean oil, peanut oil, olive oil, camellia oil, sunflower seed oil, pine oil, rapeseed oil, cottonseed oil, N-methylpyrrolidone, N,N-dimethylformamide, cyclohexanone, ethyl acetate, and n-butanol.
6. The isoxaflutole biodegradable microcapsule suspension according to claim 1, characterized in that, The mass fraction of isoxaflutole in the capsule core is 20-50%.
7. The isoxaflutole biodegradable microcapsule suspension according to claim 1, characterized in that, The mass ratio of the core to the resin-based capsule material is 1:1~3.
8. The isoxaflutole biodegradable microcapsule suspension according to claim 1, characterized in that, The mass ratio of the core to the bio-based encapsulation material is 1:0.4~1.
9. The method for preparing the isoxaflutole biodegradable microcapsule suspension according to any one of claims 1-8, characterized in that, Includes the following steps: (1) Preparation of resin-based capsule material prepolymer; (2) Mix isoxaflutole technical grade drug with solvent thoroughly to obtain core solution; (3) Mix the core solution and resin-based capsule material prepolymer evenly, adjust the pH of the system to 3.8~4.0; add composite emulsifying agent, and polymerize in situ under stirring conditions; (4) Stir and solidify at 60~70℃ and 800~1500rpm for 60~90min; adjust the pH of the system to neutral to obtain the final product.
10. The method for preparing the isoxaflutole biodegradable microcapsule suspension according to claim 9, characterized in that, The amount of composite emulsifying agent added is 20-70% of the weight of the resin-based capsule material.
